Engraftment and GVHD
| Characteristic . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | P . |
|---|---|---|---|---|
| Engraftment, no. (%) | 45 (96) | 19 (100) | 26 (93) | > .999 |
| Time to ANC > 0.5 × 109/L, d (range) | 12 (5-20) | 12 (5-20) | 12 (6-18) | .64 |
| Time to platelets > 20 × 109/L, d (range) | 15 (10-87) | 16 (11-87) | 14 (10-69) | .58 |
| Acute GVHD, no. (%) | 28 (60) | 14 (74) | 14 (50) | .13 |
| I-II | 20 (42) | 10 (53) | 10 (36) | |
| III-IV | 8 (17) | 4 (21) | 4 (14) | |
| Chronic GVHD, no. (%)* | 21 (46) | 12 (67) | 9 (33) | .03 |
| Limited | 12 (30) | 5 (28) | 7 (26) | |
| Extensive | 9 (24) | 7 (39) | 2 (7) |
| Characteristic . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | P . |
|---|---|---|---|---|
| Engraftment, no. (%) | 45 (96) | 19 (100) | 26 (93) | > .999 |
| Time to ANC > 0.5 × 109/L, d (range) | 12 (5-20) | 12 (5-20) | 12 (6-18) | .64 |
| Time to platelets > 20 × 109/L, d (range) | 15 (10-87) | 16 (11-87) | 14 (10-69) | .58 |
| Acute GVHD, no. (%) | 28 (60) | 14 (74) | 14 (50) | .13 |
| I-II | 20 (42) | 10 (53) | 10 (36) | |
| III-IV | 8 (17) | 4 (21) | 4 (14) | |
| Chronic GVHD, no. (%)* | 21 (46) | 12 (67) | 9 (33) | .03 |
| Limited | 12 (30) | 5 (28) | 7 (26) | |
| Extensive | 9 (24) | 7 (39) | 2 (7) |
ANC indicates absolute neutrophil count.
Available data on 18 patients with mutated BCR-ABL1 and 27 patients with unmutated BCR-ABL1.